Navigation Links
Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
Date:11/10/2008

candidate ELND005 (AZD-103).

On August 30, 2007, the Company announced the completion of Phase I clinical studies with ELND005 (AZD-103). Transition and its development partner Elan have performed multiple Phase I studies evaluating the safety, tolerability and pharmacokinetic profile of ELND005 (AZD-103) in healthy volunteers. Approximately 110 subjects have been exposed to ELND005 (AZD-103) in multiple Phase I studies, including single and multiple ascending dosing; pharmacokinetic evaluation of levels in the brain; and CSF and plasma studies. ELND005 (AZD-103) was safe and well-tolerated at all doses and dosing regimens examined. There were no severe or serious adverse events observed. ELND005 (AZD-103) was also shown to be orally bio-available, cross the blood-brain barrier and achieve levels in the human brain and CSF that were shown to be effective in animal models for Alzheimer's disease.

On December 21, 2007, Elan and Transition announced that the first patient had been dosed in a Phase II clinical study of ELND005 (AZD-103) in patents with Alzheimer's disease. The study is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study in approximately 340 patients with mild to moderate Alzheimer's disease. The study will evaluate both cognitive and functional endpoints, and each patient's participation is planned to last approximately 18 months.

On October 20, 2008, Elan and Transition announced the patient enrollment target for the Phase 2 clinical study of ELND005 (AZD-103) in patients with Alzheimer's disease was achieved.

TT-223 for Diabetes

Pre-clinical data in diabetes animal models demonstrate the efficacy of gastrin analogues alone, or in combination with GLP-1 analogues or epidermal growth factor analogues. In humans, Transition's Phase IIa clinical trial data showed that a 4-week therapy with TT-223 in combination with EGF (combination of gastrin analogue and epidermal growth factor analo
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Respiratory Leaders Urge Medical Community to Educate Patients Transitioning CFC to HFA Inhalers
2. Transitions Optical to Provide Free Vision Screenings at the American Diabetes Associations Feria de Salud por tu Familia(TM)
3. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
4. Schering-Plough Announces Transition of Animal Health Leadership
5. ACS Signs $27 Million Contract with Alaska to Transition Fiscal Agent Services for State Medicaid Program
6. MidSouth eHealth Alliance to Transition to Commercial Software Solution from Informatics Corporation of America
7. Transition Therapeutics Announces No Material Change
8. Transitions Optical Offers Tips on How to Protect Eyes for Outdoor Sports Fans
9. Transition Therapeutics Announces Executive Management Appointments
10. AGA Medical Announces Management Transition
11. Booth Radiology Associates Chooses IDC To Complete Its Transition To Digital Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... As payers pledge to move the bulk ... next few years, they are testing various initiatives to ... care spending they control — involved. The March issue ... tracks some of the strategies proposed by industry ... organization (ACO)-type model. , One way to get specialists ...
(Date:3/3/2015)... OH (PRWEB) March 03, 2015 On ... amended complaint in the United States District Court for ... and Financial Freedom, as well as insurance companies Balboa, ... 24, 2015 in Case No. 3:14-cv-152.) , The Plaintiff, ... with insurance companies to force her to buy too ...
(Date:3/3/2015)... March 03, 2015 Risperdal lawsuits ... market the atypical antipsychotic medication continue to move ... court documents, the South Carolina Supreme Court upheld ... & Johnson’s Janssen Pharmaceuticals unit had deceptively marketed ... while the Court’s February 25th decision characterized the ...
(Date:3/3/2015)... 2015 Loma Linda University Health announced ... well being, it will be offering new, healthier choices ... , Over the past year, a cross-section of Loma ... dietary criteria, listening to vendors, sampling their products, and ... , Most recently, a food fair was held ...
(Date:3/3/2015)... Today, Steve Weatherford, current New York Giants ... announced the donation of their brains to science during ... Month. In an effort to raise awareness for the ... health, Rice and Weatherford spoke of their experiences on ... brain health a priority to avoid the consequences of ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Examines Ways to Engage Specialists in Value-Based Payment Contracts 2Health News:AIS Newsletter Examines Ways to Engage Specialists in Value-Based Payment Contracts 3Health News:Borrower Accuses Mortgage Lenders of Racketeering in Forcing Insurance on Homeowners 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Ruling Upholding South Carolina Jury Decision in Risperdal Marketing Case 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Ruling Upholding South Carolina Jury Decision in Risperdal Marketing Case 3Health News:Loma Linda University Health Rejuvenates Its Vending Machines with Healthier Selections 2Health News:Steve Weatherford and Sidney Rice Reveal Donation for Brain Injury Awareness Month 2
... Leaders for ... World Malaria Day, World ... Bill, WASHINGTON, April 25 A volunteer nurse from,Zambia and ... to emphasize the importance of joint efforts in the,fight against malaria ...
... 24 Amneal Pharmaceuticals, LLC is,pleased to announce ... wholly-owned subsidiary, Amneal Pharmaceuticals of New York, LLC,to ... The,acquisition includes Interpharm,s facilities on Long Island, New ... technology and,processes., Amneal will use its strong ...
... Peddling Video That Does Not Show Attack ... Nurses Will Never Forget SEIU,s Violence, OAKLAND, ... brutal attack on a labor conference in Michigan April 12, ... that,does not show the violence ... as proof that the ...
... say , , THURSDAY, April 24 (HealthDay News) -- Women who ... connects the thighbone to the shinbone. Beyond the immediate pain ... that this type of injury may lead to another vexing ... Rochester, Minn., found that young women who had surgery to ...
... survival when compared to expensive lab tests , , THURSDAY, ... a second-line series of drugs for HIV/AIDS patients who ... the basis of sophisticated and expensive lab tests. , ... slightly affected if these decisions are based instead on ...
... SC, April 24 /PRNewswire/ - Ron Nabors, Chief Executive,Officer ... up with,religious, business and sports leaders in a new ... millions of deaths from,malaria, ahead of the first-ever inaugural ... year, malaria kills more than 1.5 million people in ...
Cached Medicine News:Health News:Government and Corporate Support Together Help Africans Battling Malaria, AIDS 2Health News:Government and Corporate Support Together Help Africans Battling Malaria, AIDS 3Health News:Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of Interpharm Holdings 2Health News:Nurses Blast SEIU for Deceit in Hiding Violence at Michigan Conference 2Health News:Nurses Blast SEIU for Deceit in Hiding Violence at Michigan Conference 3Health News:Women Risk Bone Loss After Knee Surgery 2Health News:Women Risk Bone Loss After Knee Surgery 3Health News:Clinical Symptoms Enough to Switch Drug Regimens for HIV Patients 2Health News:Clinical Symptoms Enough to Switch Drug Regimens for HIV Patients 3Health News:Executive Director of cbm US congratulates UN on Malaria Campaign 2
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... of the "Telemedicine and Mobile Healthcare Solutions, ... - 2020" report to their offering. ... are all terms that pertain to the use ... provide remote clinical/non-clinical healthcare services. They form the ...
(Date:3/3/2015)... 2015  Cyberonics, Inc. (NASDAQ: CYBX ), ... and management of epilepsy, today announced it will participate ... 11, 2015, in Miami . ... Executive Officer, will speak at 1:05 PM Eastern Time.  ... format, and no formal materials will be presented.  A ...
(Date:3/3/2015)... Today, the Partnership for Prescription Assistance ... research companies, unveiled a redesigned website ... and caregivers with faster, easier access to information ... assistance programs. Since its launch ... engage, educate and empower patients and caregivers to ...
Breaking Medicine Technology:Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 2Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 3Partnership for Prescription Assistance Relaunches Website with New Features for Patients and Caregivers 2
... TAXUS(R) Element(TM) Stent now available in select markets ... (NYSE: BSX ) today announced the ... Coronary Stent System in select markets worldwide. ... chromium alloy engineered specifically for coronary stent applications ...
... Pa., May 18 MEDRAD Interventional(TM)/Possis(R) today announced ... the Paccocath(R) Technology closer to market as an ... the United States and Europe who suffer from ... selection of physician investigators for U.S. clinical trials ...
Cached Medicine Technology:Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 2Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 3Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 4Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 5Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 2Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 3Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 4Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 5
... recommended for evaluating vitreoretinal relationships ... in the management of dislocated ... lens for small pupil fundus ... It provides a slightly wider ...
... new MagPlus Iridectomy Lens enhances iridectomy ... viewing area (than conventional iridectomy lens ... The bulb on this lens has ... lens) to 11.7mm. The MagPlus comes ...
... advanced fundus laser lens design with Volk ... magnification viewing and treatment of the optic ... aspheric optics provide improved performance over existing ... comes standard with LaserWindow® for optimal laser ...
... with 10mm diameter contact surface is ideal ... prematurety (ROP) and other infant conditions. It ... in the diagnosis and treatment of the ... with narrow palpebral fissures. Developed with Hideyuki ...
Medicine Products: